Inspiremd, INC Schedule 13G passive stakes

Nantahala Capital Management, LLC and its principals have reported a 9.99% beneficial ownership stake in InspireMD, Inc. as of March 31, 2026.

Velan Capital Master Fund LP and affiliated entities have reported beneficial ownership of 4.99% of InspireMD, Inc. common stock as of March 31, 2026.

Rosalind Advisors and affiliated funds reported a 9.2% beneficial ownership in InspireMD, Inc., primarily through common stock and warrants, with exercise limitations due to blocker provisions.

Aberdeen Group plc and abrdn Inc. have reported a shared beneficial ownership of 7.49% of InspireMD, Inc.'s common stock.

OrbiMed Advisors LLC has filed an Amendment No. 3 to Schedule 13G, reporting a 4.1% beneficial ownership stake in InspireMD, Inc.'s common stock.

Nantahala Capital Management, LLC and its managing members have disclosed a 9.99% beneficial ownership stake in InspireMD, Inc., including shares acquirable via warrants.

Nantahala Capital Partners Limited Partnership has reported a 5.6761% beneficial ownership stake in InspireMD, Inc., including shares acquirable via warrants.

Investment manager Marshall Wace LLP has reported a 9.99% beneficial ownership stake in InspireMD, Inc., including shares from warrants subject to a regulatory blocker.

Parkman Healthcare Partners and related entities have reported a 5.8% beneficial ownership stake in InspireMD, Inc., totaling 2,440,633 shares.

Aberdeen Group plc and its subsidiary abrdn Inc. have reported a 5.95% beneficial ownership stake in InspireMD, Inc. common stock.

Rosalind Advisors and affiliated funds disclose a 9.4% beneficial ownership in InspireMD, Inc., primarily through common shares, with warrant exercise limited by blocker provisions.

Rosalind Advisors and affiliated funds have disclosed a significant 9.4% beneficial ownership stake in InspireMD, Inc., primarily through common shares and warrants.

Rosalind Advisors and its associated funds, Rosalind Master Fund L.P. and Rosalind Opportunities Fund I L.P., reported a combined beneficial ownership of 9.4% in InspireMD, Inc. common shares, including warrants subject to a blocker provision.

Velan Capital and its affiliates have disclosed a 5.1% passive beneficial ownership stake in InspireMD, Inc., holding 2,143,698 common shares.

OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC have filed an Amendment No. 2 to their Schedule 13G, disclosing a combined beneficial ownership of 7.2% of InspireMD, Inc.'s common stock as of March 31, 2025.

Nantahala Capital Management, LLC, along with its managing members Wilmot B. Harkey and Daniel Mack, has reported a beneficial ownership of 9.99% in InspireMD, Inc.'s common stock as of March 31, 2025.

Rosalind Advisors, Inc., along with its associated funds and principals, has filed an amended Schedule 13G, disclosing a combined beneficial ownership of 7.7% in InspireMD, Inc., primarily through common shares and warrants.

Nantahala Capital Management, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed a beneficial ownership of 9.99% in InspireMD, Inc., totaling 2,709,118 shares as of December 31, 2024.

Rosalind Advisors, Inc. and its affiliated funds have filed an amended Schedule 13G, disclosing a collective passive beneficial ownership of 9.9% in InspireMD, Inc., including common shares and warrants, subject to a 9.99% ownership blocker.